SANGAMO THERAPEUTICS, INC(SGMO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

SANGAMO THERAPEUTICS, INC (SGMO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SGMO at 23.5/100 on a 32-signal composite quality model, placing it at rank #2,720 of 2,962 stocks — the bottom half of the AI-ranked universe. SGMO scores in the top quartile across revenue growth (90.0). Areas of concern include balance sheet strength (0.6) and institutional flow (0.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), SANGAMO THERAPEUTICS, INC reports quarterly revenue of $1.4M, net income of $-31.0M, free cash flow of $-19.3M. Top institutional holders of SGMO by reported 13-F value include ARMISTICE CAPITAL, VANGUARD CAPITAL MANAGEMENT, TWO SIGMA INVESTMENTS, based on the most recent SEC filings. SGMO trades on the Nasdaq exchange and files with the SEC under CIK 1001233. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SGMO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SANGAMO THERAPEUTICS, INC directly from SEC EDGAR.